NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal
Rhea-AI Filing Summary
NewAmsterdam Pharma Company N.V. filed an amendment detailing the final terms of separation and advisory agreements with former Chief Operating Officer Douglas Kling, who resigned effective August 14, 2026 to become chief executive officer of another clinical-stage biotech company. Under a letter separation agreement with a subsidiary, Kling’s unvested stock options and restricted stock units as of the separation date are canceled, except for portions that vest solely based on continued service through May 14, 2027, which may continue to vest while he serves as an advisor. The agreement also includes confidentiality, non-disparagement, non-solicitation covenants, and a release of claims. A separate advisor agreement with another subsidiary provides that Kling will deliver transition and advisory services related to the PREVAIL clinical trial of obicetrapib and other programs for a $50,000 monthly service fee plus reimbursable expenses, through May 14, 2027 unless terminated earlier.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Separation Date: August 14, 2026
Advisor monthly fee: $50,000 per month
Advisor Agreement end date: May 14, 2027
3 metrics
Separation Date
August 14, 2026
Effective date of Douglas Kling’s resignation as Chief Operating Officer
Advisor monthly fee
$50,000 per month
Service fee to Douglas Kling under the Advisor Agreement
Advisor Agreement end date
May 14, 2027
Scheduled termination date of the Advisor Agreement unless ended earlier
Key Terms
Separation Agreement, Advisor Agreement, restricted stock unit, non-solicitation, +1 more
5 terms
Separation Agreement regulatory
"On the Separation Date, Mr. Kling entered into a letter agreement (the “Separation Agreement”)"
A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.
Advisor Agreement regulatory
"Mr. Kling entered into an Advisor Agreement (the “Advisor Agreement”) with NewAmsterdam Pharma B.V."
restricted stock unit financial
"Mr. Kling’s outstanding stock option and restricted stock unit (“RSU”) awards that were not vested"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
non-solicitation regulatory
"The Separation Agreement contains restrictive covenants, including confidentiality, non-disparagement, and non-solicitation covenants"
A non-solicitation clause is a contractual promise that one party will not actively try to lure away another party’s employees, customers, or suppliers. For investors, it signals protection of a company’s workforce and client base after a deal or partnership—reducing the risk that key staff or revenue sources will be poached and therefore helping preserve the business’s value, predictability, and post-transaction earnings. Think of it as an agreement not to knock on a neighbor’s door to take their business or team.
PREVAIL clinical trial medical
"services related to the Company’s PREVAIL clinical trial of obicetrapib and other clinical programs"
FAQ
What does NewAmsterdam Pharma (NAMS) disclose in this 8-K/A amendment?
The amendment provides the detailed terms of separation and advisor agreements with former COO Douglas Kling, including treatment of equity awards and advisory compensation through May 14, 2027.
When did Douglas Kling resign as COO of NewAmsterdam Pharma (NAMS)?
Douglas Kling resigned as Chief Operating Officer effective August 14, 2026. On that same date, he entered into a Separation Agreement and an Advisor Agreement with NewAmsterdam Pharma subsidiaries.
How are Douglas Kling’s stock options and RSUs treated after leaving NewAmsterdam Pharma (NAMS)?
Unvested stock options and RSUs as of August 14, 2026 are generally canceled and forfeited, except portions eligible to vest solely through continued service until May 14, 2027 while he provides advisory services.
What compensation will Douglas Kling receive as an advisor to NewAmsterdam Pharma (NAMS)?
Under the Advisor Agreement, Kling will receive a $50,000 per month service fee plus reimbursable expenses. In return, he provides transition and advisory services related to the PREVAIL clinical trial and other programs.
How long does the Advisor Agreement with NewAmsterdam Pharma (NAMS) remain in effect?
The Advisor Agreement runs until May 14, 2027, unless it is terminated earlier under its terms. Kling’s continued service under this agreement supports vesting of certain equity awards through that date.
What restrictive covenants apply to Douglas Kling in his separation from NewAmsterdam Pharma (NAMS)?
The Separation Agreement includes confidentiality, non-disparagement, and non-solicitation covenants, along with a release of claims by Douglas Kling in connection with his departure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
